Tags

Type your tag names separated by a space and hit enter

Clinical staging of chronic lymphocytic leukemia.

Abstract

A method of clinical staging of chronic lymphocytic leukemia (CLL) has been proposed which is based on the concept that CLL is a disease of progressive accumulation of nonfunctioning lymphocytes: stage O, bone marrow and blood lymphocytosis only; stage 1, lymphocytosis with enlarged nodes; stage II, lymphocytosis with enlarged spleen or liver or both; stage III, lymphocytosis with anemia; and stage IV:lymphocytosis with thrombocytopenia. Analysis of 125 patients. in the present series showed the following median survival times (in months) from diagnosis: stage 0, is greater than 150; stage I 101; stage II, 71; stage III, 19; stage IV, 19, The median survival for the entire series was 71 mo. The prognostic significance of the stage remained even after adjustment was made for age and sex. However, both sex and age were shown to be poor predictors of survival after adjustment for stage. The method of staging proved to be a reliable predictor of survival whether used at diagnosis or during the course of the disease. The proposed staging system was an equally accurate indicator for survival when applied to two other previously published studies of large series of patients

Links

  • FREE Publisher Full Text
  • Authors

    , , , , ,

    Source

    Blood 46:2 1975 Aug pg 219-34

    MeSH

    Adrenal Cortex Hormones
    Age Factors
    Aged
    Anemia
    Blood Cell Count
    Bone Marrow Examination
    Chlorambucil
    Female
    Hematocrit
    Hepatomegaly
    Humans
    Leukemia, Lymphoid
    Lymph Nodes
    Lymphocytosis
    Male
    Middle Aged
    Prognosis
    Retrospective Studies
    Sex Factors
    Splenomegaly
    Statistics as Topic
    Thrombocytopenia

    Pub Type(s)

    Journal Article
    Research Support, U.S. Gov't, Non-P.H.S.
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    1139039

    Citation

    Rai, K R., et al. "Clinical Staging of Chronic Lymphocytic Leukemia." Blood, vol. 46, no. 2, 1975, pp. 219-34.
    Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-34.
    Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., & Pasternack, B. S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46(2), pp. 219-34.
    Rai KR, et al. Clinical Staging of Chronic Lymphocytic Leukemia. Blood. 1975;46(2):219-34. PubMed PMID: 1139039.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Clinical staging of chronic lymphocytic leukemia. AU - Rai,K R, AU - Sawitsky,A, AU - Cronkite,E P, AU - Chanana,A D, AU - Levy,R N, AU - Pasternack,B S, PY - 1975/8/1/pubmed PY - 1975/8/1/medline PY - 1975/8/1/entrez SP - 219 EP - 34 JF - Blood JO - Blood VL - 46 IS - 2 N2 - A method of clinical staging of chronic lymphocytic leukemia (CLL) has been proposed which is based on the concept that CLL is a disease of progressive accumulation of nonfunctioning lymphocytes: stage O, bone marrow and blood lymphocytosis only; stage 1, lymphocytosis with enlarged nodes; stage II, lymphocytosis with enlarged spleen or liver or both; stage III, lymphocytosis with anemia; and stage IV:lymphocytosis with thrombocytopenia. Analysis of 125 patients. in the present series showed the following median survival times (in months) from diagnosis: stage 0, is greater than 150; stage I 101; stage II, 71; stage III, 19; stage IV, 19, The median survival for the entire series was 71 mo. The prognostic significance of the stage remained even after adjustment was made for age and sex. However, both sex and age were shown to be poor predictors of survival after adjustment for stage. The method of staging proved to be a reliable predictor of survival whether used at diagnosis or during the course of the disease. The proposed staging system was an equally accurate indicator for survival when applied to two other previously published studies of large series of patients SN - 0006-4971 UR - https://www.unboundmedicine.com/medline/citation/1139039/full_citation L2 - http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=1139039 DB - PRIME DP - Unbound Medicine ER -